Patent ID: 11945874
Assignee: GENZYME CORPORATION
Field: Pharmaceuticals (Chemistry)
Classification: CPC C  A | IPC A  C

Claim 0:
1. A method for treating a cancer in a human patient in need thereof, comprising administering to the patient an effective amount of a monoclonal anti-human CD52 antibody or an antigen-binding portion thereof, wherein the light chain and heavy chain of said antibody comprise the three complementarity determining regions (CDRs) found in
a) SEQ ID NOs: 3 and 16, respectively;
b) SEQ ID NOs: 4 and 17, respectively;
c) SEQ ID NOs: 5 and 18, respectively;
d) SEQ ID NOs: 6 and 19, respectively;
e) SEQ ID NOs: 7 and 20, respectively;
f) SEQ ID NOs: 8 and 21, respectively;
g) SEQ ID NOs: 9 and 22, respectively;
h) SEQ ID NOs: 10 and 23, respectively;
i) SEQ ID NOs: 11 and 24, respectively;
j) SEQ ID NOs: 12 and 25, respectively;
k) SEQ ID NOs: 12 and 137, respectively; or
l) SEQ ID NOs: 13 and 26, respectively.